Holds one active US DMF and one valid CEP for raloxifene, filing since 2002. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for raloxifene, filing since 2013. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.
Holds one active US DMF and one valid CEP for raloxifene, filing since 2023. Its 2024 FDA inspection closed as VAI.
Holds 2 active US DMFs for raloxifene, filing since 2011. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds 2 active US DMFs for raloxifene, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for raloxifene, filing since 2021. Its GMP is recognised in 1 market.
Holds one active US DMF for raloxifene, filing since 2017. Its 2025 FDA inspection closed as NAI.
Holds one active US DMF and 2 valid CEPs for raloxifene, filing since 2012. Its 2025 FDA inspection closed as VAI.
Holds 2 active US DMFs for raloxifene, filing since 2008. Its 2024 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for raloxifene. Its 2025 FDA inspection closed as NAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Raloxifene manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free